CareDx Posts 70c Adjusted EPS for Third Quarter
CDNA has more than doubled off its 52-week low of $14.225.
Summary
CareDx reported third-quarter adjusted EPS of 70 cents, per Dow Jones Newswires, alongside EPS of 35 cents, net income of $19.3 million and revenue of $139.4 million. The print lands with the stock near its 52-week high of $73.43, so expectations were already elevated after the company raised full-year 2026 revenue guidance to $490-$500 million in August on 52% revenue growth. The prior quarter set a high bar: Q2 revenue of $131.9 million (+52% YoY) and net income of $110.6 million, though that profit was driven largely by a $113 million gain on the sale of the lab products business. Adjusted EPS strips out that kind of one-time item, so the 70-cent figure is the cleaner read on the core transplant diagnostics business.
At the time of this announcement, CDNA was trading at $71.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.7B. The 52-week trading range was $14.23 to $73.43. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.